Paraoxonases	B:C0052451
and	O
psoriasis	O
:	O
negative	O
imbalance	O
of	O
anti--oxidant	O
endogenous	O
mechanisms	O
.	O

Paraoxonases	O
and	O
psoriasis	B:C0033860
:	O
negative	O
imbalance	O
of	O
anti--oxidant	O
endogenous	O
mechanisms	O
.	O

Paraoxonases	O
and	O
psoriasis	O
:	O
negative	B:C0205160
imbalance	O
of	O
anti--oxidant	O
endogenous	O
mechanisms	O
.	O

Paraoxonases	O
and	O
psoriasis	O
:	O
negative	O
imbalance	B:C1397014
of	O
anti--oxidant	O
endogenous	O
mechanisms	O
.	O

Paraoxonases	O
and	O
psoriasis	O
:	O
negative	O
imbalance	O
of	O
anti--oxidant	B:C0003402
endogenous	O
mechanisms	O
.	O

Numerous	O
reports	O
have	O
shown	O
that	O
psoriasis	B:C0033860
patients	O
are	O
more	O
exposed	O
to	O
lipoprotein	O
peroxidation	I:C0023775
and	O
to	O
a	O
decrease	O
in	O
the	O
activity	O
of	O
paraoxonase	O
(	I:C1121571
PON	I:C1121571
)	I:C1121571
1	I:C1121571
,	O
an	O
anti-oxidant	O
and	O
anti-inflammatory	O
enzyme	O
.	O

Numerous	O
reports	O
have	O
shown	O
that	O
psoriasis	O
patients	O
are	O
more	O
exposed	O
to	O
lipoprotein	B:C0023775
peroxidation	I:C0023775
and	O
to	O
a	O
decrease	O
in	O
the	O
activity	O
of	O
paraoxonase	O
(	I:C1121571
PON	I:C1121571
)	I:C1121571
1	I:C1121571
,	O
an	O
anti-oxidant	O
and	O
anti-inflammatory	O
enzyme	O
.	O

Numerous	O
reports	O
have	O
shown	O
that	O
psoriasis	O
patients	O
are	O
more	O
exposed	O
to	O
lipoprotein	O
peroxidation	I:C0023775
and	O
to	O
a	O
decrease	O
in	O
the	O
activity	B:C2257843
of	O
paraoxonase	O
(	I:C1121571
PON	I:C1121571
)	I:C1121571
1	I:C1121571
,	O
an	O
anti-oxidant	O
and	O
anti-inflammatory	O
enzyme	O
.	O

Numerous	O
reports	O
have	O
shown	O
that	O
psoriasis	O
patients	O
are	O
more	O
exposed	O
to	O
lipoprotein	O
peroxidation	I:C0023775
and	O
to	O
a	O
decrease	O
in	O
the	O
activity	O
of	O
paraoxonase	B:C1121571
(	I:C1121571
PON	I:C1121571
)	I:C1121571
1	I:C1121571
,	O
an	O
anti-oxidant	O
and	O
anti-inflammatory	O
enzyme	O
.	O

Numerous	O
reports	O
have	O
shown	O
that	O
psoriasis	O
patients	O
are	O
more	O
exposed	O
to	O
lipoprotein	O
peroxidation	I:C0023775
and	O
to	O
a	O
decrease	O
in	O
the	O
activity	O
of	O
paraoxonase	O
(	I:C1121571
PON	I:C1121571
)	I:C1121571
1	I:C1121571
,	O
an	O
anti-oxidant	B:C0003402
and	O
anti-inflammatory	O
enzyme	O
.	O

Numerous	O
reports	O
have	O
shown	O
that	O
psoriasis	O
patients	O
are	O
more	O
exposed	O
to	O
lipoprotein	O
peroxidation	I:C0023775
and	O
to	O
a	O
decrease	O
in	O
the	O
activity	O
of	O
paraoxonase	O
(	I:C1121571
PON	I:C1121571
)	I:C1121571
1	I:C1121571
,	O
an	O
anti-oxidant	O
and	O
anti-inflammatory	B:C0003209
enzyme	O
.	O

Numerous	O
reports	O
have	O
shown	O
that	O
psoriasis	O
patients	O
are	O
more	O
exposed	O
to	O
lipoprotein	O
peroxidation	I:C0023775
and	O
to	O
a	O
decrease	O
in	O
the	O
activity	O
of	O
paraoxonase	O
(	I:C1121571
PON	I:C1121571
)	I:C1121571
1	I:C1121571
,	O
an	O
anti-oxidant	O
and	O
anti-inflammatory	O
enzyme	B:C0014442
.	O

Thus	O
,	O
it	O
has	O
been	O
suggested	O
that	O
malfunction	O
of	O
the	O
anti-oxidant	B:C0003402
system	I:C0003402
and	O
an	O
increased	O
production	O
of	O
reactive	O
oxygen	I:C0162772
species	I:C0162772
drive	O
immune	O
inflammatory	O
events	O
,	O
that	O
result	O
in	O
progressive	O
skin	O
cell	I:C0814995
damage	O
in	O
patients	O
with	O
psoriasis	O
.	O

Thus	O
,	O
it	O
has	O
been	O
suggested	O
that	O
malfunction	O
of	O
the	O
anti-oxidant	O
system	I:C0003402
and	O
an	O
increased	O
production	B:C3714634
of	O
reactive	O
oxygen	I:C0162772
species	I:C0162772
drive	O
immune	O
inflammatory	O
events	O
,	O
that	O
result	O
in	O
progressive	O
skin	O
cell	I:C0814995
damage	O
in	O
patients	O
with	O
psoriasis	O
.	O

Thus	O
,	O
it	O
has	O
been	O
suggested	O
that	O
malfunction	O
of	O
the	O
anti-oxidant	O
system	I:C0003402
and	O
an	O
increased	O
production	O
of	O
reactive	B:C0162772
oxygen	I:C0162772
species	I:C0162772
drive	O
immune	O
inflammatory	O
events	O
,	O
that	O
result	O
in	O
progressive	O
skin	O
cell	I:C0814995
damage	O
in	O
patients	O
with	O
psoriasis	O
.	O

Thus	O
,	O
it	O
has	O
been	O
suggested	O
that	O
malfunction	O
of	O
the	O
anti-oxidant	O
system	I:C0003402
and	O
an	O
increased	O
production	O
of	O
reactive	O
oxygen	I:C0162772
species	I:C0162772
drive	O
immune	O
inflammatory	O
events	O
,	O
that	O
result	O
in	O
progressive	O
skin	B:C0814995
cell	I:C0814995
damage	O
in	O
patients	O
with	O
psoriasis	O
.	O

Thus	O
,	O
it	O
has	O
been	O
suggested	O
that	O
malfunction	O
of	O
the	O
anti-oxidant	O
system	I:C0003402
and	O
an	O
increased	O
production	O
of	O
reactive	O
oxygen	I:C0162772
species	I:C0162772
drive	O
immune	O
inflammatory	O
events	O
,	O
that	O
result	O
in	O
progressive	O
skin	O
cell	I:C0814995
damage	O
in	O
patients	O
with	O
psoriasis	B:C0033860
.	O

The	O
PON	B:C0052451
protein	O
family	I:C1335532
,	O
including	O
PON1	O
,	O
PON2	O
and	O
PON3	O
,	O
is	O
one	O
of	O
the	O
most	O
important	O
endogenous	O
defense	O
mechanisms	I:C0011142
against	O
oxidative	O
stress	I:C0242606
.	O

The	O
PON	O
protein	B:C1335532
family	I:C1335532
,	O
including	O
PON1	O
,	O
PON2	O
and	O
PON3	O
,	O
is	O
one	O
of	O
the	O
most	O
important	O
endogenous	O
defense	O
mechanisms	I:C0011142
against	O
oxidative	O
stress	I:C0242606
.	O

The	O
PON	O
protein	O
family	I:C1335532
,	O
including	O
PON1	B:C1257646
,	O
PON2	O
and	O
PON3	O
,	O
is	O
one	O
of	O
the	O
most	O
important	O
endogenous	O
defense	O
mechanisms	I:C0011142
against	O
oxidative	O
stress	I:C0242606
.	O

The	O
PON	O
protein	O
family	I:C1335532
,	O
including	O
PON1	O
,	O
PON2	B:C0755726
and	O
PON3	O
,	O
is	O
one	O
of	O
the	O
most	O
important	O
endogenous	O
defense	O
mechanisms	I:C0011142
against	O
oxidative	O
stress	I:C0242606
.	O

The	O
PON	O
protein	O
family	I:C1335532
,	O
including	O
PON1	O
,	O
PON2	O
and	O
PON3	B:C1447656
,	O
is	O
one	O
of	O
the	O
most	O
important	O
endogenous	O
defense	O
mechanisms	I:C0011142
against	O
oxidative	O
stress	I:C0242606
.	O

The	O
PON	O
protein	O
family	I:C1335532
,	O
including	O
PON1	O
,	O
PON2	O
and	O
PON3	O
,	O
is	O
one	O
of	O
the	O
most	O
important	O
endogenous	O
defense	B:C0011142
mechanisms	I:C0011142
against	O
oxidative	O
stress	I:C0242606
.	O

The	O
PON	O
protein	O
family	I:C1335532
,	O
including	O
PON1	O
,	O
PON2	O
and	O
PON3	O
,	O
is	O
one	O
of	O
the	O
most	O
important	O
endogenous	O
defense	O
mechanisms	I:C0011142
against	O
oxidative	B:C0242606
stress	I:C0242606
.	O

In	O
the	O
present	O
study	B:C2603343
,	O
we	O
investigated	O
PON	O
gene	I:C0017337
expression	O
in	O
psoriasis	O
and	O
in	O
cutaneous	O
oxidative	O
stress	I:C0242606
.	O

In	O
the	O
present	O
study	O
,	O
we	O
investigated	O
PON	B:C0017337
gene	I:C0017337
expression	O
in	O
psoriasis	O
and	O
in	O
cutaneous	O
oxidative	O
stress	I:C0242606
.	O

In	O
the	O
present	O
study	O
,	O
we	O
investigated	O
PON	O
gene	I:C0017337
expression	B:C0017262
in	O
psoriasis	O
and	O
in	O
cutaneous	O
oxidative	O
stress	I:C0242606
.	O

In	O
the	O
present	O
study	O
,	O
we	O
investigated	O
PON	O
gene	I:C0017337
expression	O
in	O
psoriasis	B:C0033860
and	O
in	O
cutaneous	O
oxidative	O
stress	I:C0242606
.	O

In	O
the	O
present	O
study	O
,	O
we	O
investigated	O
PON	O
gene	I:C0017337
expression	O
in	O
psoriasis	O
and	O
in	O
cutaneous	B:C0221912
oxidative	O
stress	I:C0242606
.	O

In	O
the	O
present	O
study	O
,	O
we	O
investigated	O
PON	O
gene	I:C0017337
expression	O
in	O
psoriasis	O
and	O
in	O
cutaneous	O
oxidative	B:C0242606
stress	I:C0242606
.	O

The	O
study	B:C2603343
population	O
included	O
10	O
patients	O
affected	O
by	O
moderate	O
-	O
to	O
-	O
severe	O
plaque	O
psoriasis	I:C0033860
and	O
15	O
healthy	O
donors	O
who	O
have	O
undergone	O
to	O
plastic	O
surgery	I:C0677616
,	O
were	O
used	O
as	O
control	O
.	O

The	O
study	O
population	B:C1257890
included	O
10	O
patients	O
affected	O
by	O
moderate	O
-	O
to	O
-	O
severe	O
plaque	O
psoriasis	I:C0033860
and	O
15	O
healthy	O
donors	O
who	O
have	O
undergone	O
to	O
plastic	O
surgery	I:C0677616
,	O
were	O
used	O
as	O
control	O
.	O

The	O
study	O
population	O
included	O
10	O
patients	O
affected	O
by	O
moderate	O
-	O
to	O
-	O
severe	O
plaque	B:C0033860
psoriasis	I:C0033860
and	O
15	O
healthy	O
donors	O
who	O
have	O
undergone	O
to	O
plastic	O
surgery	I:C0677616
,	O
were	O
used	O
as	O
control	O
.	O

The	O
study	O
population	O
included	O
10	O
patients	O
affected	O
by	O
moderate	O
-	O
to	O
-	O
severe	O
plaque	O
psoriasis	I:C0033860
and	O
15	O
healthy	O
donors	B:C0013018
who	O
have	O
undergone	O
to	O
plastic	O
surgery	I:C0677616
,	O
were	O
used	O
as	O
control	O
.	O

The	O
study	O
population	O
included	O
10	O
patients	O
affected	O
by	O
moderate	O
-	O
to	O
-	O
severe	O
plaque	O
psoriasis	I:C0033860
and	O
15	O
healthy	O
donors	O
who	O
have	O
undergone	O
to	O
plastic	B:C0677616
surgery	I:C0677616
,	O
were	O
used	O
as	O
control	O
.	O

Skin	B:C0191321
punch	I:C0191321
biopsies	I:C0191321
of	O
lesional	O
and	O
non	O
lesional	I:C1123023
psoriatic	I:C1123023
skin	I:C1123023
were	O
performed	O
for	O
analysis	O
of	O
PON2	O
and	O
PON3	O
gene	O
expression	I:C0017262
.	O

Skin	O
punch	I:C0191321
biopsies	I:C0191321
of	O
lesional	B:C1123023
and	O
non	O
lesional	I:C1123023
psoriatic	I:C1123023
skin	I:C1123023
were	O
performed	O
for	O
analysis	O
of	O
PON2	O
and	O
PON3	O
gene	O
expression	I:C0017262
.	O

Skin	O
punch	I:C0191321
biopsies	I:C0191321
of	O
lesional	O
and	O
non	B:C1123023
lesional	I:C1123023
psoriatic	I:C1123023
skin	I:C1123023
were	O
performed	O
for	O
analysis	O
of	O
PON2	O
and	O
PON3	O
gene	O
expression	I:C0017262
.	O

Skin	O
punch	I:C0191321
biopsies	I:C0191321
of	O
lesional	O
and	O
non	O
lesional	I:C1123023
psoriatic	I:C1123023
skin	I:C1123023
were	O
performed	O
for	O
analysis	B:C0936012
of	O
PON2	O
and	O
PON3	O
gene	O
expression	I:C0017262
.	O

Skin	O
punch	I:C0191321
biopsies	I:C0191321
of	O
lesional	O
and	O
non	O
lesional	I:C1123023
psoriatic	I:C1123023
skin	I:C1123023
were	O
performed	O
for	O
analysis	O
of	O
PON2	B:C1418755
and	O
PON3	O
gene	O
expression	I:C0017262
.	O

Skin	O
punch	I:C0191321
biopsies	I:C0191321
of	O
lesional	O
and	O
non	O
lesional	I:C1123023
psoriatic	I:C1123023
skin	I:C1123023
were	O
performed	O
for	O
analysis	O
of	O
PON2	O
and	O
PON3	B:C1418756
gene	O
expression	I:C0017262
.	O

Skin	O
punch	I:C0191321
biopsies	I:C0191321
of	O
lesional	O
and	O
non	O
lesional	I:C1123023
psoriatic	I:C1123023
skin	I:C1123023
were	O
performed	O
for	O
analysis	O
of	O
PON2	O
and	O
PON3	O
gene	B:C0017262
expression	I:C0017262
.	O

In	O
addition	O
,	O
oxidation	B:C0030011
assays	O
in	O
ex	O
vivo	O
full	O
-	O
thickness	O
healthy	O
skin	O
organ	O
cultures	I:C0029205
were	O
performed	O
.	O

In	O
addition	O
,	O
oxidation	O
assays	B:C0005507
in	O
ex	O
vivo	O
full	O
-	O
thickness	O
healthy	O
skin	O
organ	O
cultures	I:C0029205
were	O
performed	O
.	O

In	O
addition	O
,	O
oxidation	O
assays	O
in	O
ex	O
vivo	O
full	O
-	O
thickness	O
healthy	O
skin	B:C1123023
organ	O
cultures	I:C0029205
were	O
performed	O
.	O

In	O
addition	O
,	O
oxidation	O
assays	O
in	O
ex	O
vivo	O
full	O
-	O
thickness	O
healthy	O
skin	O
organ	B:C0029205
cultures	I:C0029205
were	O
performed	O
.	O

No	O
significant	O
differences	O
were	O
observed	O
between	O
PON2	B:C1418755
and	O
PON3	O
gene	O
expression	I:C0017262
in	O
psoriatic	O
lesional	I:C1123023
and	O
non	O
lesional	I:C1123023
skin	I:C1123023
compared	O
with	O
healthy	O
controls	O
.	O

No	O
significant	O
differences	O
were	O
observed	O
between	O
PON2	O
and	O
PON3	B:C1418756
gene	O
expression	I:C0017262
in	O
psoriatic	O
lesional	I:C1123023
and	O
non	O
lesional	I:C1123023
skin	I:C1123023
compared	O
with	O
healthy	O
controls	O
.	O

No	O
significant	O
differences	O
were	O
observed	O
between	O
PON2	O
and	O
PON3	O
gene	B:C0017262
expression	I:C0017262
in	O
psoriatic	O
lesional	I:C1123023
and	O
non	O
lesional	I:C1123023
skin	I:C1123023
compared	O
with	O
healthy	O
controls	O
.	O

No	O
significant	O
differences	O
were	O
observed	O
between	O
PON2	O
and	O
PON3	O
gene	O
expression	I:C0017262
in	O
psoriatic	B:C1123023
lesional	I:C1123023
and	O
non	O
lesional	I:C1123023
skin	I:C1123023
compared	O
with	O
healthy	O
controls	O
.	O

No	O
significant	O
differences	O
were	O
observed	O
between	O
PON2	O
and	O
PON3	O
gene	O
expression	I:C0017262
in	O
psoriatic	O
lesional	I:C1123023
and	O
non	B:C1123023
lesional	I:C1123023
skin	I:C1123023
compared	O
with	O
healthy	O
controls	O
.	O

H2O2	B:C0020281
treatment	O
induced	O
a	O
significant	O
decrease	O
of	O
PON2	O
and	O
PON3	O
expression	O
in	O
ex	O
vivo	O
full	O
-	O
thickness	O
healthy	O
skin	O
organ	O
cultures	I:C0029205
;	O
conversely	O
the	O
pre-treatment	O
of	O
samples	O
with	O
the	O
anti-oxidant	O
reagent	I:C0003402
N	O
-	I:C0001047
acetyl	I:C0001047
-	I:C0001047
L-cysteine	I:C0001047
(	O
N	O
-	I:C0001047
acetyl	I:C0001047
-	I:C0001047
L-	I:C0001047
cysteine	I:C0001047
)	O
induced	O
a	O
significant	O
increase	O
.	O

H2O2	O
treatment	O
induced	O
a	O
significant	O
decrease	O
of	O
PON2	B:C1418755
and	O
PON3	O
expression	O
in	O
ex	O
vivo	O
full	O
-	O
thickness	O
healthy	O
skin	O
organ	O
cultures	I:C0029205
;	O
conversely	O
the	O
pre-treatment	O
of	O
samples	O
with	O
the	O
anti-oxidant	O
reagent	I:C0003402
N	O
-	I:C0001047
acetyl	I:C0001047
-	I:C0001047
L-cysteine	I:C0001047
(	O
N	O
-	I:C0001047
acetyl	I:C0001047
-	I:C0001047
L-	I:C0001047
cysteine	I:C0001047
)	O
induced	O
a	O
significant	O
increase	O
.	O

H2O2	O
treatment	O
induced	O
a	O
significant	O
decrease	O
of	O
PON2	O
and	O
PON3	B:C1418756
expression	O
in	O
ex	O
vivo	O
full	O
-	O
thickness	O
healthy	O
skin	O
organ	O
cultures	I:C0029205
;	O
conversely	O
the	O
pre-treatment	O
of	O
samples	O
with	O
the	O
anti-oxidant	O
reagent	I:C0003402
N	O
-	I:C0001047
acetyl	I:C0001047
-	I:C0001047
L-cysteine	I:C0001047
(	O
N	O
-	I:C0001047
acetyl	I:C0001047
-	I:C0001047
L-	I:C0001047
cysteine	I:C0001047
)	O
induced	O
a	O
significant	O
increase	O
.	O

H2O2	O
treatment	O
induced	O
a	O
significant	O
decrease	O
of	O
PON2	O
and	O
PON3	O
expression	B:C0017262
in	O
ex	O
vivo	O
full	O
-	O
thickness	O
healthy	O
skin	O
organ	O
cultures	I:C0029205
;	O
conversely	O
the	O
pre-treatment	O
of	O
samples	O
with	O
the	O
anti-oxidant	O
reagent	I:C0003402
N	O
-	I:C0001047
acetyl	I:C0001047
-	I:C0001047
L-cysteine	I:C0001047
(	O
N	O
-	I:C0001047
acetyl	I:C0001047
-	I:C0001047
L-	I:C0001047
cysteine	I:C0001047
)	O
induced	O
a	O
significant	O
increase	O
.	O

H2O2	O
treatment	O
induced	O
a	O
significant	O
decrease	O
of	O
PON2	O
and	O
PON3	O
expression	O
in	O
ex	O
vivo	O
full	O
-	O
thickness	O
healthy	O
skin	B:C1123023
organ	O
cultures	I:C0029205
;	O
conversely	O
the	O
pre-treatment	O
of	O
samples	O
with	O
the	O
anti-oxidant	O
reagent	I:C0003402
N	O
-	I:C0001047
acetyl	I:C0001047
-	I:C0001047
L-cysteine	I:C0001047
(	O
N	O
-	I:C0001047
acetyl	I:C0001047
-	I:C0001047
L-	I:C0001047
cysteine	I:C0001047
)	O
induced	O
a	O
significant	O
increase	O
.	O

H2O2	O
treatment	O
induced	O
a	O
significant	O
decrease	O
of	O
PON2	O
and	O
PON3	O
expression	O
in	O
ex	O
vivo	O
full	O
-	O
thickness	O
healthy	O
skin	O
organ	B:C0029205
cultures	I:C0029205
;	O
conversely	O
the	O
pre-treatment	O
of	O
samples	O
with	O
the	O
anti-oxidant	O
reagent	I:C0003402
N	O
-	I:C0001047
acetyl	I:C0001047
-	I:C0001047
L-cysteine	I:C0001047
(	O
N	O
-	I:C0001047
acetyl	I:C0001047
-	I:C0001047
L-	I:C0001047
cysteine	I:C0001047
)	O
induced	O
a	O
significant	O
increase	O
.	O

H2O2	O
treatment	O
induced	O
a	O
significant	O
decrease	O
of	O
PON2	O
and	O
PON3	O
expression	O
in	O
ex	O
vivo	O
full	O
-	O
thickness	O
healthy	O
skin	O
organ	O
cultures	I:C0029205
;	O
conversely	O
the	O
pre-treatment	O
of	O
samples	O
with	O
the	O
anti-oxidant	B:C0003402
reagent	I:C0003402
N	O
-	I:C0001047
acetyl	I:C0001047
-	I:C0001047
L-cysteine	I:C0001047
(	O
N	O
-	I:C0001047
acetyl	I:C0001047
-	I:C0001047
L-	I:C0001047
cysteine	I:C0001047
)	O
induced	O
a	O
significant	O
increase	O
.	O

H2O2	O
treatment	O
induced	O
a	O
significant	O
decrease	O
of	O
PON2	O
and	O
PON3	O
expression	O
in	O
ex	O
vivo	O
full	O
-	O
thickness	O
healthy	O
skin	O
organ	O
cultures	I:C0029205
;	O
conversely	O
the	O
pre-treatment	O
of	O
samples	O
with	O
the	O
anti-oxidant	O
reagent	I:C0003402
N	B:C0001047
-	I:C0001047
acetyl	I:C0001047
-	I:C0001047
L-cysteine	I:C0001047
(	O
N	O
-	I:C0001047
acetyl	I:C0001047
-	I:C0001047
L-	I:C0001047
cysteine	I:C0001047
)	O
induced	O
a	O
significant	O
increase	O
.	O

H2O2	O
treatment	O
induced	O
a	O
significant	O
decrease	O
of	O
PON2	O
and	O
PON3	O
expression	O
in	O
ex	O
vivo	O
full	O
-	O
thickness	O
healthy	O
skin	O
organ	O
cultures	I:C0029205
;	O
conversely	O
the	O
pre-treatment	O
of	O
samples	O
with	O
the	O
anti-oxidant	O
reagent	I:C0003402
N	O
-	I:C0001047
acetyl	I:C0001047
-	I:C0001047
L-cysteine	I:C0001047
(	O
N	B:C0001047
-	I:C0001047
acetyl	I:C0001047
-	I:C0001047
L-	I:C0001047
cysteine	I:C0001047
)	O
induced	O
a	O
significant	O
increase	O
.	O

Interestingly	O
,	O
no	O
significant	O
alterations	O
were	O
reported	O
for	O
PON2	B:C1418755
and	O
PON3	O
expression	O
in	O
ex	O
vivo	O
full	O
-	O
thickness	O
healthy	O
skin	O
organ	O
cultures	I:C0029205
stimulated	O
with	O
IL	O
-	I:C0384648
17	I:C0384648
.	O

Interestingly	O
,	O
no	O
significant	O
alterations	O
were	O
reported	O
for	O
PON2	O
and	O
PON3	B:C1418756
expression	O
in	O
ex	O
vivo	O
full	O
-	O
thickness	O
healthy	O
skin	O
organ	O
cultures	I:C0029205
stimulated	O
with	O
IL	O
-	I:C0384648
17	I:C0384648
.	O

Interestingly	O
,	O
no	O
significant	O
alterations	O
were	O
reported	O
for	O
PON2	O
and	O
PON3	O
expression	B:C0017262
in	O
ex	O
vivo	O
full	O
-	O
thickness	O
healthy	O
skin	O
organ	O
cultures	I:C0029205
stimulated	O
with	O
IL	O
-	I:C0384648
17	I:C0384648
.	O

Interestingly	O
,	O
no	O
significant	O
alterations	O
were	O
reported	O
for	O
PON2	O
and	O
PON3	O
expression	O
in	O
ex	O
vivo	O
full	O
-	O
thickness	O
healthy	O
skin	B:C1123023
organ	O
cultures	I:C0029205
stimulated	O
with	O
IL	O
-	I:C0384648
17	I:C0384648
.	O

Interestingly	O
,	O
no	O
significant	O
alterations	O
were	O
reported	O
for	O
PON2	O
and	O
PON3	O
expression	O
in	O
ex	O
vivo	O
full	O
-	O
thickness	O
healthy	O
skin	O
organ	B:C0029205
cultures	I:C0029205
stimulated	O
with	O
IL	O
-	I:C0384648
17	I:C0384648
.	O

Interestingly	O
,	O
no	O
significant	O
alterations	O
were	O
reported	O
for	O
PON2	O
and	O
PON3	O
expression	O
in	O
ex	O
vivo	O
full	O
-	O
thickness	O
healthy	O
skin	O
organ	O
cultures	I:C0029205
stimulated	O
with	O
IL	B:C0384648
-	I:C0384648
17	I:C0384648
.	O

Taken	O
together	O
our	O
findings	B:C0243095
have	O
revealed	O
that	O
a	O
strong	O
pro-oxidative	O
activity	I:C2266999
is	O
not	O
effectively	O
countered	O
by	O
anti-oxidant	O
endogenous	O
mechanisms	O
both	O
in	O
psoriatic	O
skin	O
and	O
in	O
ex	O
vivo	O
experimental	O
model	I:C0086272
.	O

Taken	O
together	O
our	O
findings	O
have	O
revealed	O
that	O
a	O
strong	O
pro-oxidative	B:C2266999
activity	I:C2266999
is	O
not	O
effectively	O
countered	O
by	O
anti-oxidant	O
endogenous	O
mechanisms	O
both	O
in	O
psoriatic	O
skin	O
and	O
in	O
ex	O
vivo	O
experimental	O
model	I:C0086272
.	O

Taken	O
together	O
our	O
findings	O
have	O
revealed	O
that	O
a	O
strong	O
pro-oxidative	O
activity	I:C2266999
is	O
not	O
effectively	O
countered	O
by	O
anti-oxidant	B:C0003402
endogenous	O
mechanisms	O
both	O
in	O
psoriatic	O
skin	O
and	O
in	O
ex	O
vivo	O
experimental	O
model	I:C0086272
.	O

Taken	O
together	O
our	O
findings	O
have	O
revealed	O
that	O
a	O
strong	O
pro-oxidative	O
activity	I:C2266999
is	O
not	O
effectively	O
countered	O
by	O
anti-oxidant	O
endogenous	O
mechanisms	O
both	O
in	O
psoriatic	B:C0033860
skin	O
and	O
in	O
ex	O
vivo	O
experimental	O
model	I:C0086272
.	O

Taken	O
together	O
our	O
findings	O
have	O
revealed	O
that	O
a	O
strong	O
pro-oxidative	O
activity	I:C2266999
is	O
not	O
effectively	O
countered	O
by	O
anti-oxidant	O
endogenous	O
mechanisms	O
both	O
in	O
psoriatic	O
skin	B:C1123023
and	O
in	O
ex	O
vivo	O
experimental	O
model	I:C0086272
.	O

Taken	O
together	O
our	O
findings	O
have	O
revealed	O
that	O
a	O
strong	O
pro-oxidative	O
activity	I:C2266999
is	O
not	O
effectively	O
countered	O
by	O
anti-oxidant	O
endogenous	O
mechanisms	O
both	O
in	O
psoriatic	O
skin	O
and	O
in	O
ex	O
vivo	O
experimental	B:C0086272
model	I:C0086272
.	O

